(Q47252798)

http://europepmc.org/abstract/MED/28975219

12 January 2018

title

Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer (English)

1 reference

http://europepmc.org/abstract/MED/28975219

12 January 2018

author name string

Koji Haratani

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6583041&resulttype=core&format=json

15 May 2020

Hidetoshi Hayashi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6583041&resulttype=core&format=json

15 May 2020

Yasutaka Chiba

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6583041&resulttype=core&format=json

15 May 2020

Keita Kudo

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6583041&resulttype=core&format=json

15 May 2020

Kimio Yonesaka

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6583041&resulttype=core&format=json

15 May 2020

Ryoji Kato

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6583041&resulttype=core&format=json

15 May 2020

Hiroyasu Kaneda

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6583041&resulttype=core&format=json

15 May 2020

Yoshikazu Hasegawa

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6583041&resulttype=core&format=json

15 May 2020

Kaoru Tanaka

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6583041&resulttype=core&format=json

15 May 2020

Masayuki Takeda

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6583041&resulttype=core&format=json

15 May 2020

Kazuhiko Nakagawa

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6583041&resulttype=core&format=json

15 May 2020

publication date

21 September 2017

1 reference

http://europepmc.org/abstract/MED/28975219

12 January 2018

published in

JAMA Oncology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6583041&resulttype=core&format=json

15 May 2020

volume

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6583041&resulttype=core&format=json

15 May 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6583041&resulttype=core&format=json

15 May 2020

page(s)

374-378

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6583041&resulttype=core&format=json

Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis

15 May 2020

cites work

1 reference

12 December 2020

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

1 reference

12 December 2020

Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression.

1 reference

12 December 2020

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

1 reference

12 December 2020

Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes.

1 reference

12 December 2020

Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab

1 reference

12 December 2020

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

1 reference

12 December 2020

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

1 reference

12 December 2020

Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review.

1 reference

12 December 2020

Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi-institutional retrospective study.

1 reference

12 December 2020

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

1 reference

12 December 2020

Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer

1 reference

12 December 2020

Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer

1 reference

12 December 2020

Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma

1 reference

12 December 2020

10.1001/JAMAONCOL.2017.2925

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6583041&resulttype=core&format=json

15 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6583041&resulttype=core&format=json

15 May 2020

1 reference